TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02971813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook
Description: 1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: 1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time.
Study: NCT01466036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg QD orally in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg QD orally in cycles of 28 days
Study: NCT03799822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG Oral Tablet
Description: replacement of warfarin by rivaroxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG Oral Tablet
Description: replacement of warfarin by rivaroxaban

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MK-7 2000µg thrice weekly
Description: dietary supplement of vitamin K2 MK-7 2000µg thrice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K Antagonist - Drug
Description: treatment with a vitamin K antagonist
Study: NCT01480895

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lifestyle instruction for Jews and Bedouin GDM women.
Description: Every several months the women had instructions and checkups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle instruction for Jews and Bedouin GDM women.
Description: Every several months the women had instructions and checkups.
Study: NCT05995990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raman Spectrometry
Description: Laboratory technique of Raman Spectrometry
Study: NCT04339595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
Study: NCT02962089

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched chain amino acids (BCAA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01358396

Intervention type: OTHER
Intervention: Respond to therapy for diabetic macular edema
Description: Correlate HBA1c with visual acuity outcome to therapy.
Study: NCT00152906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) or highly conformal (CRT)
Description: SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
Study: NCT02361957

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ecologic 825
Description: Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
Study: NCT04010032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus
Description: bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion
Description: Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
Study: NCT03861650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Physiological saline is added in control group to act as placebo
Study: NCT06383065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT Group
Description: Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
Study: NCT03326739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Line Placement
Description: arterial line placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Line Placement
Description: arterial line placement
Study: NCT04188470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: person-centered care model
Description: A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
Study: NCT03239184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT01747226

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride rinse
Description: rinse with 15 ml for 1 minute

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Halita
Description: rinsing with 15 ml for 1 minute

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meridol Halitosis
Description: rinsing with 15 ml for 1 minute

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: rinsing with 15ml for 1 minute
Study: NCT00431678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin + Ceftriaxone
Description: Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
Study: NCT03130608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
Study: NCT03686514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLUARIX QUADRIVALENT
Description: The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLUARIX QUADRIVALENT
Description: The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
Study: NCT01641874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Directional specific exercise
Study: NCT02409784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-KD
Description: Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-KD
Description: After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
Study: NCT01641874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evidence based exercise
Description: Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
Study: NCT04242173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
Study: NCT01904058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid
Study: NCT03959072

Intervention type: DEVICE
Intervention: Robotic CTO PCI
Description: Randomized to robotic CTO PCI.

Intervention type: PROCEDURE
Intervention: Conventional (Manual) CTO PCI
Description: Randomized to manual CTO PCI.
Study: NCT01435070

Intervention type: PROCEDURE
Intervention: Kirschner wire fixation
Description: The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment.

Intervention type: PROCEDURE
Intervention: Volar Locking Plate fixation
Description: The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
Study: NCT03428607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 160mg QD
Study: NCT01408680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
Study: NCT00751790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin embonate (INN)
Description: Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
Study: NCT01253824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IKH-01
Description: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
Study: NCT00151996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate + SPD503 (Guanfacine hydrochloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine + SPD503
Study: NCT02074956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
Study: NCT01673724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole
Description: pramipexole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: bromocriptine
Study: NCT04125797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of adhesive
Description: Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of adhesive
Description: Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of adhesive
Description: Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
Study: NCT02688842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin target-eluting coronary stent systems (38mm)
Study: NCT01515176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02000986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
Description: Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
Study: NCT03901287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual energy CT scans
Description: The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
Study: NCT02191085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track
Description: In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP.
Study: NCT01860053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
Study: NCT03428607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg BID
Study: NCT02998892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise Training
Description: Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Microbursts of Activity
Description: Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
Study: NCT04070378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
Study: NCT01806870

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc and SAMe
Description: If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
Study: NCT04215081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training using ExoAtlet exoskeleton
Description: Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
Study: NCT00661752

Intervention type: DEVICE
Intervention: quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac
Description: Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR

Intervention type: DEVICE
Intervention: quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac
Description: Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR

Intervention type: DEVICE
Intervention: quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac
Description: Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
Study: NCT02361957

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02460835

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiation Therapy
Study: NCT02274558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: NBI-98854 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: NBI-98854 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: NBI-98854 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NBI-98854 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NBI-98854 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NBI-98854 placebo capsules
Study: NCT02320617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Magnetic Resonance Imaging
Description: Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
Study: NCT01404962

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haemophilus influenza type b conjugate vaccine
Description: Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.